HLA Blocking Assay

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The specificity of the antibody is very important. One of the most common and effective methods to test the specificity of antibodies is the antigen blocking test. Creative Biolabs provides human leukocyte antigen (HLA) blocking assay to test the specificity of HLA antibodies.

Antigen Blocking Test

A combination of blocking antigen and antibody is used to block the binding of antibodies and specific antigens in the process of antibody and natural antigens binding. The binding of antibodies and antigens is well specific if the binding of antibodies and natural antigens can be blocked by the characteristics of the antigen. Antigen blocking test is an effective method for all the antibodies, including the specificity of the Immunofluorescence (IF)/immunocytochemistry (ICC) antibody.

The process of antigen blocking experiments for IF/ICC antibody refers to incubation of antigen and antibody firstly, and then the mixture was added to the natural cells or tissues, which make antibodies and natural antigen binding. The blocking antigen includes proteins or polypeptides, which have been used to prepare the IF/ICC antibody.

In Vivo HLA Blockade

Workflow of in vivo HLA blockade. Fig.1 Workflow of in vivo HLA blockade.

MHC class II blockade reduces allogeneic T cell-mediated injury and CD8⁺ CTL-associated transcripts in human arterial grafts. Existential studies have proven this view by in vivo HLA-DR blocking assay. Here are some relevant findings as follows:

HLA-DR blockade reduces CD8⁺ T cell infiltration and CTL development within implanted allogeneic vessel segments in vivo.

Anti-HLA-DRα F(ab)'₂ fragment significantly reduces total intimal T cell infiltration as detected by IF (A) and CD8⁺ T cell-associated transcripts of cytokines and CTL effector molecules in rejected artery grafts at 21 days (B) as detected by qPCR normalized to either total mRNA or T cell-specific mRNA.

Fig.2 Results of HLA-DR blockade. (Abrahimi, 2016)

HLA-DR blockade reduces acute T cell-mediated injury to implanted allogeneic vessel segments in vivo.

In an MHC-mismatched model of arterial rejection by allogeneic T cells, blockade of class II MHC by anti-HLA-DRα F(ab)'₂ fragment reduces intimal area expansion and increases lumen area as measured by H&E and EVG staining (A) and reduces disruption of enterochromaffin cell (EC) lining the vessel lumen, a hallmark of intimal arteritis/endothelialitis, as measured by percent of circumferential coverage (B).

Fig.3 Results of HLA-DR blockade. (Abrahimi, 2016)

With the in-depth study of HLA, Creative Biolabs offers a complete range portfolio of assays for HLA Testing, including HLA blocking assay. If you are interested in our HLA blocking assay, please feel free to contact us directly.

Reference

Abrahimi, P.; et al. Blocking MHC class II on human endothelium mitigates acute rejection. JCI Insight. 2016, 1(1): e85293.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION